Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zimmer Biomet Holdings (ZBH – Research Report), Annexon Biosciences (ANNX – Research Report) and Cytokinetics (CYTK – Research Report).
Zimmer Biomet Holdings (ZBH)
In a report issued on May 8, Josh Jennings from TD Cowen maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $143.00. The company’s shares closed last Monday at $119.27.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Currently, the analyst consensus on Zimmer Biomet Holdings is a Moderate Buy with an average price target of $138.91, a 14.2% upside from current levels. In a report issued on April 29, Wells Fargo also maintained a Hold rating on the stock with a $132.00 price target.
See today’s best-performing stocks on TipRanks >>
Annexon Biosciences (ANNX)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Annexon Biosciences today. The company’s shares closed last Monday at $4.86.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of
Currently, the analyst consensus on Annexon Biosciences is a Strong Buy with an average price target of $16.20, representing a 227.3% upside. In a report released today, Needham also reiterated a Buy rating on the stock with a $16.00 price target.
Cytokinetics (CYTK)
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Cytokinetics today and set a price target of $86.00. The company’s shares closed last Monday at $59.00.
According to TipRanks.com, Devarakonda is a 4-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $96.69, which is a 52.7% upside from current levels. In a report issued on May 8, Goldman Sachs also maintained a Buy rating on the stock with a $85.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZBH:
- Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024
- Zimmer Biomet price target lowered to $130 from $137 at Truist
- Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
- Zimmer Biomet backs FY24 adjusted EPS view $8.00-$8.15, consensus $8.06
- Zimmer Biomet reports Q1 adjusted EPS $1.94, consensus $1.87
